Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Semaxanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 6/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 3/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 7/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 5/20 | 1.00 |
| ▸ | FLT3 | P36888 | 3/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 3/20 | 1.00 |
| ▸ | CSF1R | P07333 | 2/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Semaxanib SCHEMBL19572 | 1.00 | RET (1.00) | RETKDRALKFLT3FLT1 | |
| Semaxanib SCHEMBL19571 | 1.00 | RET (1.00) | RETKDRALKFLT3FLT1 | |
| Semaxanib SCHEMBL29351025 | 1.00 | RET (1.00) | RETKDRALKFLT3FLT1 | |
| Semaxanib SCHEMBL28266617 | 1.00 | RET (1.00) | RETKDRALKFLT3FLT1 | |
| SCHEMBL32676579 | 0.87 | RET (0.77) | RETKDRALKFLT3FLT1 | |
| SCHEMBL32676595 | 0.87 | RET (0.77) | RETKDRALKFLT3FLT1 | |
| SCHEMBL32676489 | 0.87 | RET (0.77) | RETKDRALKFLT3FLT1 | |
| SCHEMBL5200799 | 0.85 | KDR (0.74) | RETKDRALKFLT3FLT1 | |
| SCHEMBL5200796 | 0.85 | KDR (0.74) | RETKDRALKFLT3FLT1 | |
| SCHEMBL8211131 | 0.84 | RET (0.73) | RETKDRALKFLT3FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000691-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | JENNINGS BARBARA BROOKE (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2025244963-A1 | ECTEINASCIDIN DERIVATIVES AND METHODS OF USE THEREOF AS ANTITUMOR AGENTS | MERCK SHARP & DOHME LLC (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4630001-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | Merck Sharp & Dohme LLC (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-4608398-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | Merck Sharp & Dohme LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025136841-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-119923398-A | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20250136697-A1 | METHODS AND COMPOSITIONS COMPRISING B7H3 CHIMERIC ANTIGEN RECEPTORS | SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST (US) | 2025-05-01 | — | — | US | disclosed |
| US-12173071-B2 | Methods and compositions comprising B7H3 chimeric antigen receptors | SEATTLE CHILDREN'S HOSPITAL (US) | 2024-12-24 | — | — | US | disclosed |
| CN-112805006-B | PRMT5 inhibitors | 默沙东有限责任公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2024123585-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-13 | — | — | WO | disclosed |
| CN-115087638-A | PRMT5 inhibitor | 默沙东公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-115003303-A | PRMT5 inhibitor | 默沙东公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-106008460-B | Pharmaceutically acceptable salts of 2- {4- [ (3S) -piperidin-3-yl ] phenyl } -2H-indazole-7-carboxamide | 默沙东公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114761432-A | Dosing regimen of anti-CD 27 antibodies for treatment of cancer | 默沙东公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-110272426-B | Alkynyl (hetero) aromatic ring compounds for inhibiting protein kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2022-05-31 | — | — | CN | disclosed |
| WO-2022080473-A1 | NERVE CELL ACTIVATOR | 三沢幸子 | 2022-04-21 | — | — | WO | disclosed |
| EP-3982998-A1 | COMPOSITIONS AND METHODS FOR SUBCUTANEOUS ADMINISTRATION OF CANCER IMMUNOTHERAPY | Alkermes Pharma Ireland Limited (IE) | 2022-04-20 | — | — | EP | disclosed |
| CN-110194772-B | Alkynyl (hetero) aromatic ring compounds for inhibiting protein kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2022-04-05 | — | — | CN | disclosed |
| WO-2022046771-A1 | JUVENILE PROTECTIVE FACTORS TO ARREST AND REVERSE AGING IN THE ENTERIC NERVOUS SYSTEM | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-03-03 | — | — | WO | disclosed |
| CN-108289922-B | Therapeutic methods and compositions for treating non-small cell lung cancer | 友杏生技医药股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000691-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | PDK1, IP6K1, IP6K3 | KDR 536/4885FLT1 741/4885FLT4 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.